categories G2-G5), with 55.3 % of patients exhibiting values of 60-89 ml/min/1.73 m 2 (G2). PTH (r = −0.3329, p < 0.0001) and FGF23 (r = −0.3641, p < 0.0001) levels inversely correlated with eGFR, whereas calcidiol levels and serum phosphate levels did not. Overall, PTH levels were above normal in 34.9 % of patients. This proportion increased from 19.4 % in G1 category patients, to 33.7 % in G2 category patients and 56.6 % in G3-G5 category patients (p < 0.001). In multivariate analysis, eGFR and calcidiol levels were the main independent determinants of serum PTH. The mean FGF23 levels were 69.9 (54.6-96.2) relative units (RU)/ml, and 33.2 % of patients had FGF23 levels above 85.5 RU/ml (18.4 % in G1 category patients, 30.0 % in G2 category patients, and 59.2 % in G3-G5 category patients; p < 0.001). In multivariate analysis, eGFR was the main predictor of FGF23 levels. Increased phosphate levels were present in 0.7 % of the whole sample: 0 % in G1 category patients, 0.3 % in G2 category patients, and 2.8 % in G3-G5 category patients (p = 0.011). Almost 90 % of Abstract Chronic kidney disease (CKD)-mineral and bone disorder (MBD) is characterized by increased circulating levels of parathormone (PTH) and fibroblast growth factor 23 (FGF23), bone disease, and vascular calcification, and is associated with adverse outcomes. We studied the prevalence of mineral metabolism disorders, and the potential relationship between decreased estimated glomerular filtration rate (eGFR) and CKD-MBD in coronary artery disease patients in a cross-sectional study of 704 outpatients 7.5 ± 3.0 months after an acute coronary syndrome. The mean eGFR (CKD Epidemiology Collaboration formula) was 75.8 ± 19.1 ml/min/1.73 m 2 . Our patients showed lower calcidiol plasma levels than a healthy cohort from the same geographical area. In the case of men, this finding was present despite similar creatinine levels in both groups and older age of the healthy subjects. Most patients (75.6 %) had an eGFR below 90 ml/min/1.73 m 2 (eGFR E. González-Parra and Á. Aceña contributed equally to this work. . Then, mild decreases in eGFR must be taken in consideration by the clinician because they are associated with progressive abnormalities of mineral metabolism.
patients had calcidiol insufficiency without significant differences among the different degrees of eGFR. In conclusion, in patients with coronary artery disease there is a large prevalence of increased FGF23 and PTH levels. These findings have an independent relationship with decreased eGFR, and are evident at an eGFR of 60-89 ml/min/1.73 m
Introduction
The KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease define chronic kidney disease (CKD) as the presence for more than 3 months of abnormalities of kidney structure or function, with implications for health [1] . CKD is classified on the basis of cause, glomerular filtration rate (GFR) category, and albuminuria category (CGA classification). Six GFR categories are recognized: G1 (normal or high, 90 ml/ min/1.73 m 2 or greater), G2 (mildly decreased, 60-89 ml/ min/1.73 m ). CKD is defined as either an estimated GFR (eGFR) of less than 60 ml/min/1.73 m 2 or evidence of kidney injury such as a urinary albumin/creatinine ratio (UACR) greater than 30 mg/g [1] . The basis of this classification is the increased relative risk of adverse outcomes associated with either an eGFR of less than 60 ml/min/1.73 m 2 or a UACR greater than 30 mg/g [1] . These adverse outcomes include all-cause and cardiovascular death, progressive CKD, and acute kidney injury. Although renal outcomes are clearly associated with these two cut-off points (eGFR less than 60 ml/min/1.73 m 2 or UACR greater than 30 mg/g), an increased risk of all-cause and cardiovascular death is observed in patients with reduced eGFR (eGFR category G2, 60-89 ml/min/1.73 m 2 ) even when the UACR is below 30 mg/g [1] . The KDIGO 2012 guidelines recommend reporting eGFR in adults obtained with the 2009 CKD Epidemiology Collaboration (CKD-EPI) creatinine equation [1] , because it provides an accurate estimate of eGFR in all GFR categories [1, 2] . In patients with heart failure, the CKD-EPI equations were superior to the older Modification of Diet in Renal Disease (MDRD) equation for predicting mortality, especially in patients with GFR greater than 60 ml/min [3] . In this regard, the MDRD equation was generated from CKD patients participating in a clinical trial and is not accurate for patients with GFR greater than 60 ml/min. In the past decade many countries followed the recommendation that whenever serum creatinine is measured, MDRD-derived eGFR is reported simply as greater than 60 ml/min/1.73 m 2 when it is above this value, providing only the specific result when it is less than 60 ml/min/1.73 m 2 [4] . Together with the lack of routine UACR assessment, reporting eGFR as greater than 60 ml/min/1.73 m 2 on the basis of the MDRD equation may lead to underdiagnosis of CKD by many non-nephrologists. This may deprive patients of early diagnosis and management of CKD complications, such as mineral and bone disorders (MBD). CKD-MBD is an early and progressive complication of CKD associated with accelerated vascular calcification, left ventricular hypertrophy, and increased cardiovascular morbidity and mortality [5, 6] . The earliest manifestation of CKD-MBD is associated with disruption of phosphate homeostasis, vascular calcification, and accelerated aging [7] [8] [9] .
The novelty of the work reported here is that we have studied the status of the components of mineral metabolism in patients with stable coronary artery disease from the Biomarkers in Acute Coronary Syndrome and Biomarkers in Acute Myocardial Infarction studies [10] by assessing eGFR by the CKD-EPI equation, according to the most recent CKD guidelines [1] . We divided the population into three groups according to the GFR (less than 60 ml/min/1.73 m 2 , 60-89 ml/min/1.73 m 2 , and 90 ml/ min/1.73 m 2 or greater) showing that mild decreases in GFR have an impact on CKD-MBD parameters. This suggests that all patients with coronary artery disease should be screened for CKD with use of the CKD-EPI equation to detect those with an eGFR of 60-89 ml/min/1.73 m 2 .
Materials and methods

Study design
The research protocol was approved by the ethics committees of the hospitals, and all patients signed informed consent documents. The Biomarkers in Acute Coronary Syndrome and Biomarkers in Acute Myocardial Infarction studies enrolled patients admitted to four hospitals in the area of Madrid (Spain) with either non-ST-elevation acute coronary syndrome or ST-elevation acute myocardial infarction [10] . Non-ST-elevation acute coronary syndrome was defined as rest anginal pain lasting more than 20 min in the previous 24 h, or new-onset class III-IV angina, along with transient ST depression or T wave inversion in the electrocardiogram considered diagnostic by the attending cardiologist and/or troponin level elevation. STelevation myocardial infarction was defined as symptoms compatible with angina lasting more than 20 min and ST elevation in two adjacent leads in the electrocardiogram without response to nitroglycerin, and troponin level elevation. Exclusion criteria were age greater than 85 years, coexistence of other significant cardiac disorders except left ventricular hypertrophy secondary to hypertension, coexistence of any illness or toxic habits that could limit patient survival, impossibility to perform revascularization when indicated, and subjects in whom follow-up was not possible. To avoid variability of findings due to an excessive heterogeneity in the intervals between the acute event and blood sampling, patients not clinically stable at day 6 of the index event were excluded. Between July 2006 and April 2010, 1898 patients were discharged from the study hospitals with a diagnosis of non-ST-elevation acute coronary syndrome or ST-elevation acute myocardial infarction. Eight hundred thirty-eight patients were enrolled in the study. The remaining patients were not enrolled because of age greater than 85 years (17.3 %), presence of disorders or toxic habits limiting survival (29.0 %), impossibility to perform cardiac revascularization (14.5 %), coexistence of other significant cardiopathy (6.8 %), impossibility to perform follow-up (12.0 %), clinical instability beyond day 6 of the index event (9.1 %), refusal to participate in the study (2.0 %), and impossibility for the investigators to enroll them (9.3 %). Of the 838 patients enrolled, seven died after discharge and 709 returned for an outpatient visit and blood sampling between January 2007 and February 2011 (between 6 and 12 months after discharge). Five patients were lost to follow-up, leaving a total of 704 patients for analysis.
Biochemical studies
At the outpatient visit, a complete set of clinical variables were recorded and 12-h fasting venous blood samples were collected in EDTA, centrifuged at 2500g for 10 min, and plasma stored at −80 °C in the Biobank of IIS-Fundación Jiménez Díaz until assessment of 25-hydroxyvitamin D (calcidiol), fibroblast growth factor 23 (FGF23), and intact parathormone (PTH) in the Laboratory of Nephrology and Mineral Metabolism at Gómez-Ulla Hospital. The remaining analytes were assessed in the Vascular Pathology Laboratory and the Biochemistry Laboratory at Fundación Jiménez Díaz. The investigators who performed the laboratory studies were blinded to the clinical data. Plasma calcidiol levels were quantified by a chemiluminescent immunoassay with a LIAISON ® XL analyzer (LIAISON calcidiol total assay, marketed as 25OH vitamin D total assay, DiaSorin, Saluggia, Italy), FGF23 was measured by an enzyme-linked immunosorbent assay which recognizes epitopes within the carboxyl-terminal portion of FGF23 (human FGF23, C-terminal; Immutopics, San Clemente, CA, USA), intact PTH was analyzed by a second-generation automated chemiluminescence method (Elecsys 2010 platform, Roche Diagnostics, Mannheim, Germany), phosphate was determined by an enzymatic method (Integra 400 analyzer, Roche Diagnostics, Mannheim, Germany), and high-sensitivity C-reactive protein (hsCRP) was assessed by latex-enhanced immunoturbidimetry (ADVIA 2400 chemistry system, Siemens, Germany). Kidney function was estimated by the CKD-EPI eGFR equation [11] .
Statistical analysis
Quantitative data that followed a normal distribution (Kolmogorov-Smirnov test) are presented as the mean ± standard deviation, and those not normally distributed are displayed as the median (interquartile range). Qualitative variables are displayed as percentages. Calcidiol levels were assessed as four clinically relevant categories: 10.0 ng/ml or less (severe deficiency), 10.01-20.00 ng/ml (moderate deficiency), 20.01-30.0 ng/ml (insufficiency/ suboptimal levels), and more than 30 ng/ml (sufficiency). To assess correlations, some values were log-transformed, and Pearson's r was obtained. Multivariate linear regression models were used to identify factors independently associated with serum PTH or FGF23. Models were built with forward stepwise procedures to maximize r 2 with the smallest number of predictor variables. Clearly asymmetric variables were log-transformed. Results are expressed as coefficients and the 95 % confidence interval, p values, and the adjusted r 2 value. The statistical significance of variables in the models was assessed by ANOVA for variables with a normal distribution and Kruskal-Wallis tests for variables not normally distributed. Analyses were performed with SPSS 19.0 (SPSS, New York, NY, USA) and Instat 3.10 (GraphPad Software, La Jolla, CA, USA).
Results
Renal function and CKD-MBD parameters were assessed in 704 outpatients 7.5 ± 3.0 months after a non-ST-elevation acute coronary syndrome or an ST-elevation acute myocardial infarction. Table 1 shows epidemiological and analytical parameters for the whole cohort and for different KDIGO 2012 eGFR categories (G1, G2, and G3-G5). The mean eGFR estimated by the CKD-EPI formula was 75.8 ± 19.1 ml/min/1.73 m 2 . Most patients (75.5 %) had a low eGFR (GFR categories G2-G5, less than 90 ml/ min/1.73 m 2 ). More than 50 % of patients had an eGFR of 60-89 ml/min/1.73 m 2 (G2). In the absence of albuminuria data, G2 patients are not considered as having CKD [1] . Compared with patients with a normal eGFR (G1), patients with a decreased eGFR were older, less frequently male, and had higher hsPCR values, suggesting systemic inflammation (Table 1) . Patients with a decreased eGFR also had greater prevalence of cerebrovascular events, peripheral artery disease, atrial fibrillation, and reduced ejection fraction.
Only four patients (0.6 %) were taking vitamin D supplements and none were taking cinacalcet or phosphate binders. Thus, the cohort can be considered to reflect natural history CKD-MBD parameters in coronary artery disease patients. Overall, calcidiol, PTH, FGF23, and serum phosphate levels differed between the three eGFR groups (G1, G2, and G3-G5, Table 1 ).
However, only PTH and FGF23 levels progressively changed according to progressively lower eGFR (Fig. 1 ). This is in accordance with our current understanding of CKD-MBD. Thus, although there are CKD-associated factors (e.g., proteinuria with loss of protein-bound vitamin D) that may impact on calcidiol levels, the main risk factors for low calcidiol levels (low sun exposure and low vitamin D intake) are not CKD specific [12] . In this regard, the mean calcidiol level was 19.61 ± 8.23 ng/ml, and 89.6 % of patients in all eGFR categories had calcidiol insufficiency or deficiency (less than 30 ng/ml; Table 1 ), and there was no correlation between calcidiol levels and eGFR (Table 2) . Serum phosphate levels did not correlate with eGFR either (Table 2) . In this regard, the vast majority of patients had normal serum phosphate levels, and only five (0.7 %) had a serum phosphate level greater than 4.5 mg/dl. This is not surprising because, given the toxicity of excess phosphate [13, 14] , compensatory mechanisms such as increased serum FGF23 and PTH levels are activated very early in the course of CKD and hyperphosphatemia is typically not observed until eGFR categories G4 and mainly G5 [2, 15] . Thus, the main CKD-MBD-associated changes in the present coronary artery disease cohort were observed for PTH and FGF23.
The median serum PTH level was 59.7 (45.5-77.3) pg/ ml and progressively increased as the eGFR decreased as assessed by eGFR category (Table 1, Fig. 1 ) or as a continuous variable (r −0.3329, p < 0.0001; Table 2 , Fig. 2 ). Overall, 35 % of the study patients displayed above-normal PTH levels (more than 74 pg/ml according to the normal range for the laboratory). Among patients with normal renal function (eGFR category G1), 19.4 % had high PTH levels. In eGFR category G1, low calcidiol levels are inversely correlated with drivers of high PTH levels ( Table 2 ; r −0.300, p < 0.0001), although eGFR was also a contributor (r −0.164, p 0.0326). We should remember that the original definition of normal calcidiol levels was based on their association with normal PTH levels [16] . In this regard, calcidiol levels also inversely correlate with serum PTH levels in all individual eGFR categories ( Table 2) . Furthermore, in multivariate analysis, eGFR and calcidiol levels were the main independent determinants of serum PTH levels. Serum phosphate (negative correlation), hsCRP (negative correlation), and FGF23 (positive correlation) were also independently correlated with PTH (Table 3 ).
The median serum FGF23 level was 69.9 (54.6-96.2) relative units (RU)/ml, and 33.2 % of patients had an FGF23 level greater than 85.5 RU/ml, which is considered to confer a higher risk of CKD progression [17] . In eGFR category G1, 18.4 % of patients have FGF23 values above this limit. The driver of these early changes was unclear, and could be related to variables not assessed in the present study, such as dietary phosphate and low kidney klotho levels [8, 9, [18] [19] [20] . Both within eGFR categories G2 and G3-G5 and for the overall cohort, a clear inverse correlation of FGF23 levels with eGFR was observed. In multivariate analysis (Table 4) , eGFR was the main predictor of FGF23 levels. Additional independent predictors were sex, phosphate, hsCRP, and PTH. Contrary to the findings for PTH, phosphate and hsCRP were directly correlated to FGF23 levels. Table 5 shows the distribution of eGFR and mineral metabolism parameters across the different age ranges.
The PTH/phosphate and FGF23/phosphate ratios increased as the eGFR category worsened (Table 1) , reflecting the need for higher concentrations of phosphaturic hormones to maintain normal phosphate levels as glomerular phosphate filtration decreases and progressive resistance to their kidney effects develops [19] .
Finally, we compared our data on calcidiol plasma levels with those of a healthy cohort of 657 men and 1154 women recently reported by Olmos et al. [21] . In men, as expected, calcidiol values were lower in our study than in the healthy cohort (20.2 ± 8.4 ng/ml vs. 23.5 ± 7.7 ng/ml; p < 0.001). This was so in the absence of significant differences in creatinine plasma levels (1.09 ± 0.33 mg/dl vs. 1.08 ± 0.2 mg/ dl; p = 0.503). Even more, our patients were younger than those of the healthy cohort (59.8 ± 11.7 years vs. 64.6 ± 8.4 years; p < 0.001). Our female patients also had lower calcidiol levels (17.9 ± 7.3 mg/dl vs. 22.1 ± 7.9 mg/ dl; p < 0.001). However, opposite to what we observed in men, age (66.4 ± 12.7 years vs. 63.2 ± 9.8 years; p < 0.001) and plasma creatinine levels were higher than those of healthy individuals (0.94 ± 0.36 mg/dl vs. 0.90 ± 0.20 mg/dl; p = 0.002).
Discussion
The main findings of this study are that most patients with coronary artery disease have a decrease in calcidiol plasma levels, which is more prevalent than in healthy individuals from the same geographical area. Of special interest, in the subgroup of men this finding was present despite similar creatinine plasma levels in both populations. In addition, 
2 ) assessed by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula and following the KDIGO 2012 eGFR category definition [1] Categorical variables are presented as percentages, quantitative variables with a normal distribution are presented as the mean ± standard deviation, and those not normally distributed are presented as the median (with the interquartile range in parentheses).
FGF23 fibroblast growth factor 23, HDL high-density lipoprotein, HS high sensitivity, LDL low-density lipoprotein, NSTEACS non-ST-elevation acute coronary syndrome, PTH parathormone, RU relative units, STEMI ST-elevation myocardial infarction a Refers to the comparison among G1, G2, and G3-G5 groups All n = 704 (100 %) Category G1 eGFR ≥ 90 (n = 172) (24. the age of our male patients was significantly lower than that of the healthy cohort, meaning that the lower calcidiol levels found in men with coronary artery disease may not be attributed to a poorer renal function or to an older age. It must be emphasized than patients with life-threatening comorbidities, among which were those receiving hemodialysis, were excluded from our study. Of great interest, the abnormalities in mineral metabolism were present in CKD-MBD with an eGFR of less than 90 ml/min/1.73 m 2 . There is a high prevalence of a reduced eGFR in patients with coronary artery disease. Although the current data do not allow a firm diagnosis of CKD for patients with eGFR categories G1 and G2, due to the lack of confirmation in a second dataset 3 months apart and the lack of availability of UACRs (as is frequently the case for cardiology patients), we provide evidence that these low eGFRs, even within eGFR category G1, may be adversely affecting CKD-MBD parameters such as PTH and FGF23 levels and, thus, may be potentially contributing to findings frequently observed in coronary artery disease patients such as left ventricular hypertrophy, vascular and valve calcification, and high mortality rates [20, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] .
CKD is present in a substantial proportion of patients with coronary artery disease. In pooled data from five international multicenter trials, 16 % of 13,307 patients with acute coronary syndrome had an eGFR below 60 ml/ [33] . More recently, the CLARIFY registry showed that 22.1 % of patients with stable coronary artery disease have an eGFR below this level [34] , a proportion similar to the 20.3 % described in the present study. In addition, 76 % of patients had an eGFR assessed by the CKD-EPI equation below 90 ml/min/1.73 m 2 . This cut-off point includes a much higher percentage of patients than the usual limit of 60 ml/min/1.73 m 2 to define CKD on the basis of eGFR alone (60 ml/min/1.73 m 2 ). However, contrary to the common perception that mild decreases in eGFR (G1, G2) may be associated with treatable biochemical abnormalities, we describe the frequent occurrence of increased serum PTH and FGF23 levels even at these early stages. Indeed, PTH and FGF23 levels negatively correlated with eGFR in the whole cohort, where eGFR was the main determinant of PTH and FGF23 levels in multivariate analysis. Furthermore, eGFR correlated with PTH levels even in eGFR category G1 and with FGF23 levels in eGFR category G2, suggesting an impact of eGFR on CKD-MBD even at eGFRs that are often considered "normal" for age.
Patients with CKD gradually lose the capacity to excrete phosphate because of reduced nephron numbers, which results in a trend toward a positive phosphate balance [19] . Mild decreases in eGFR (eGFR category G2) are associated with decreased glomerular filtration of phosphate and compensatory responses to maintain phosphate homeostasis, such an increased FGF23 and PTH levels [8, 19] . In this regard, high FGF23 levels indicate a physiological response to a state of phosphate excess that is due to an increase in dietary intake or a reduction in kidney excretion, and may be associated with soft tissue phosphate deposition, even in the absence of high serum phosphate levels. Uremia favors vascular deposition of phosphate [35] . FGF23 protects against excess phosphate by decreasing kidney tubular phosphate reabsorption, thus promoting urinary phosphate excretion, and by inhibiting activation of calcidiol to 1,25-dihydroxyvitamin D in kidney tubular cells [36, 37] . The resulting low 1,25-dihydroxyvitamin D levels impair calcium and phosphate absorption in the gut, thus protecting against dietary phosphate excess. However, low 1,25-dihydroxyvitamin D levels promote a trend toward hypocalcemia and increased PTH concentration [19, 38] . The high prevalence of nutritional and sun-induced vitamin D deficiency in the general population and in coronary artery disease patients could cause a decrease in calcidiol availability for activation in the kidneys [39] . As a result of high FGF23 and PTH levels, serum phosphate levels remain within normal limits up to very advanced CKD stages [5, 15] .
Patients with reduced GFR or CKD are at increased risk of adverse cardiac outcomes [15, 40, 41] . In patients with no CKD, bone mineral disorders have also been linked to the severity of coronary artery disease, as seen on coronary angiography [42] , as well as to increased carotid intima-media thickness [43] and ventricular hypertrophy [44] . Serum levels of calcidiol, PTH, phosphate, and FGF23 have been associated with prevalent and incident cardiovascular disease, suggesting a role for bioregulators of bone and mineral metabolism in cardiovascular health.
Observational studies have clearly linked high FGF23 and low calcidiol levels with adverse patient outcomes [12, 20, [22] [23] [24] [25] [26] [27] [28] [45] [46] [47] . Studies linking high serum PTH levels with adverse outcomes are more controversial [29] [30] [31] [32] . Because in the present study calcidiol levels were not related to eGFR and high phosphate levels were very uncommon, we will discuss only FGF23 and PTH. Higher FGF23 levels are independently associated with death and cardiovascular events in coronary patients and in the community as well as with risk of stroke independently of renal function [17, 20, [22] [23] [24] [25] [26] [27] [28] . In the Heart and Soul Study, patients in the highest tertile of FGF23 level had an 83 % increase in cardiovascular events [22] . The increased risk conferred by higher FGF23 levels may be related to the status of FGF23 as a marker of phosphate excess, as a marker of klotho deficiency, or direct adverse effects of FGF23 promoting left ventricular hypertrophy or vascular calcification [6, 9, 19, 20, 26] . In his regard, although serum phosphate levels were mostly within normal limits in our study, there is a graded independent relation between higher levels of serum phosphate and the risk of death and cardiovascular events in persons with prior myocardial infarction, most of whom had serum phosphate levels within the normal range [48] , as well as in other non-CKD populations [13, 14, 49, 50] .
In our study, multivariate analysis showed that eGFR is the main determinant of serum FGF23 levels. In addition, phosphate, hsCRP and PTH were directly correlated to FGF23 levels. These associations may be causal, according to knowledge gathered from experimental animal models. Thus, excess phosphate is the main physiological stimulus increasing FGF23 levels [19, 50] . In addition, systemic inflammation lowers kidney klotho levels [51] and decreased kidney klotho levels alone may result in higher FGF23 levels [9] . The existence of these independent drivers of FG23 levels may explain the presence of high FGF23 levels in 18 % of patients with an eGFR of 90 ml/ min/1.73 m 2 or greater. Thus, either systemic inflammation or excess dietary phosphate may result in increased FGF23 secretion. In this regard, the multivariate model explained only 18 % of the FGF23 level variability. These data suggest an important role of additional factors, potentially including an excess of phosphate ingestion.
Elevated PTH level has been associated with a greater prevalence and incidence of cardiovascular risk factors and predicts a greater likelihood of prevalent and incident disease and death [28] , even in patients with stable coronary artery disease [29] . In the Uppsala Longitudinal Study in Adult Men (ULSAM) community-based study, higher PTH level was independently associated with a 38 % greater risk of cardiovascular death [30] . However, no association between PTH and the risk of coronary heart disease was observed in the Health Professionals Followup Study in 51,529 healthy professionals aged 40-75 years in 1986 during 10 years of follow-up [31] , and a recent meta-analysis did not show an association between PTH and all-cause death in CKD [32] . In our study there was a high incidence of elevated PTH levels in coronary artery disease patients. In multivariate analysis low eGFRs and low calcidiol levels were the main independent determinants of higher serum PTH levels. In addition, there was an independent negative correlation between serum phosphate and PTH. The negative correlation between serum phosphate and PTH levels clearly differs from the positive correlation between serum phosphate and FGF23 levels. This observation is consistent with excess phosphate being the primary driver of FGF23 secretion, whereas hypocalcemia and low calcidiol levels are the key drivers of PTH secretion. Thus, when PTH levels are increased in response to low calcium levels or low vitamin D levels (which also impair phosphate absorption from the gut), the resulting increased urinary phosphate excretion may lead to lower serum phosphate levels. The independent positive correlation between PTH and FGF23 may be the result of complex interactions between both molecules. Thus, FGF23 directly suppresses PTH secretion [52] . However, the trend toward hypocalcemia as a result of FGF23-mediated suppression of vitamin D activation may increase PTH levels [19, 38] . Finally, the presence of diabetes correlated inversely with PTH levels. As hyperglycemia is known to suppress PTH secretion [53] , it could be hypothesized that this feature could interfere with the development of atherosclerosis in diabetes. However, low serum PTH levels may have also an adverse effect on the cardiovascular system through different mechanisms. Low PTH levels decrease bone turnover, and may lead to adynamic bone disease [54] , a well-recognized clinical entity in CKD which is associated not only with increased risk of bone fractures but also vascular calcifications, which may at least partially explain the association of this disorder with increased mortality rates. Moreover, diabetes, as well as aging, has been associated with this disorder [54] . Then, there is no reason to hypothesize that PTH suppression in diabetes could modify favorably the clinical course of diabetes-related atherosclerotic changes.
This study has some limitations. Urine albumin, klotho, and calcium plasma levels were not measured, and renal echography was not performed. Such data could have added important information to this article.
In conclusion, patients with coronary artery disease have low plasma levels of calcidiol even when compared with a healthy cohort. Even more, in the subgroup of men these results were present without differences in creatinine plasma levels and with coronary patients being younger than healthy controls. In addition, in our population, this decrease in calcidiol and the increase in FGF23 and PTH levels are evident at an eGFR below 90 ml/min/1.73 m 2 . The current standard in many countries for eGFR assessment is the MDRD formula, and actual results are only reported if the eGFR is below 60 ml/min/1.73 m 2 . This approach results in unawareness by the treating physicians of low eGFR in coronary artery disease patients. We propose that the KDIGO 2012 guidelines for CKD be followed and that reporting of actual eGFR values based on the CKD-EPI formula be implemented. Further studies are needed to explore whether reducing phosphorus intake and/or vitamin D supplementation will restore normal PTH and FGF23 levels in coronary artery disease patients with a reduced eGFR and whether this intervention improves patient outcomes.
